Friday 02 October | 12:45 - 13:30
Friday 02 October | 12:45 - 13:30

Transforming Long-term Vision: Innovations in Technology
Moderator(s): M.S. Figueroa Spain C. Regillo USA
M.S. Figueroa Spain
The journey of VEGF inhibition and future perspectives
C. Regillo USA
Transforming treatment in nAMD
M.S. Figueroa Spain C. Regillo USA
Experts in conversation: innovations in drug delivery and the impact on clinical practice
M.S. Figueroa Spain C. Regillo USA
Q&A Session
Friday 02 October | 13:00 - 13:45
Friday 02 October | 13:00 - 13:45

Reimagining The Future for IRD Patients: From Diagnosis to Treatment Management
Moderator(s): B.P. Leroy Belgium
B.P. Leroy Belgium
Welcome and introduction
A. Daly Ireland
Pathway to diagnosis of an inherited retinal dystrophy (IRD): the patient perspective
C.B. Hoyng The Netherlands
Focusing on referral: getting to know your IRD network
B.P. Leroy Belgium
Genetic counselling: interpreting and evaluating a diagnosis
D. Fischer UK
Notes from a Treatment Center: from referral to follow-up
B.P. Leroy Belgium
Summary and close
Friday 02 October | 16:45 - 17:45
Friday 02 October | 16:45 - 17:45

Emerging Anti-VEGF Treatment in nAMD: Evaluating the Latest Evidence and Exploring Clinical Cases
Moderator(s): A. Loewenstein Israel
A. Loewenstein Israel
Welcome and introduction
S. Sadda USA
The importance of retinal fluid in the management of patients with nAMD
F. Holz Germany
Latest evidence on the treatment of patients with nAMD
Clinical case discussion
Live Q&A

Optimizing Patient Outcomes in nAMD: The Key Principles
Moderator(s): P. Lanzetta Italy
P. Lanzetta Italy
Welcome and introductions
M. Stewart USA
Considering drug dynamics: what is the relevance for clinical practice?
N. Holekamp USA
Fluid in focus: advancing our understanding
N. Eter Germany
Proactive and practical: extending intervals with aflibercept
P. Lanzetta Italy
Expert exchange: practical insights from the clinic
Friday 02 October | 17:00 - 18:00
Friday 02 October | 17:00 - 18:00

AMD Innovations Platform: Innovations in AMD Treatment Address Unmet Clinical Needs
Moderator(s): A. Loewenstein Israel S. Wolf Switzerland
A. Loewenstein Israel
Welcome and ARS questions
S. Wolf Switzerland
Review of EURETINA AMD clinical trends survey data
S. Wolf Switzerland
The AMD treatment burden
R. Tadayoni France
Current and future applications of longer lasting anti-VEGF therapeutics
D. Pieramici USA
Insights and pearls on implantable sustained release technologies
A. Loewenstein Israel
Artificial intelligence (AI) in AMD treatment decision-making
Panel discussion
A. Loewenstein Israel
Final ARS and key takeaway messages
Supported by:
Saturday 03 October | 11:30 - 12:15
Saturday 03 October | 11:30 - 12:15

Vision in Focus: Delivering Optimized Patient Outcomes in DME in the Real World
Moderator(s): I. Pearce UK
I. Pearce UK
Welcome and introductions
J. Koroblenik France
Early intensive and proactive long-term treatment: delivering on the promise of RCT-like outcomes in the real world
V. Chaudhary Canada
Retinal vascular disease: differentiation in treatment and the view of international guidelines
F. Behar-Cohen France
All in the action: multi-targeting three underlying pathways
I. Pearce UK
Experience from the experts: panel discussion
Saturday 03 October | 11:45 - 12:30
Saturday 03 October | 11:45 - 12:30

AMD Fluid Resolution Platform: Treatment Outcome Goals for the Wet AMD Patient
Moderator(s): F. G. Holz Germany
F. G. Holz Germany
Welcome and ARS questions
F. G. Holz Germany
Review of EURETINA AMD clinical trends survey data
G. Staurenghi Italy
Multi-modal imaging and its importance in diagnosing and monitoring AMD
M. Zinkernagel Switzerland
Wet AMD treatments: outcome goals
J. Monés Spain
Wet AMD treatments: protocols and therapy decisions
P. Kaiser USA
Panel discussion: anti-VEGF safety concerns in a real-world setting
F. G. Holz Germany
Final ARS and key takeaway messages
Supported by:

Innovations to Further Advance Modern Vitreoretinal Surgery
Moderator(s): R. Tadayoni France
R. Tadayoni France
Introduction
S. Rizzo Italy
How the vitreous cutter with bevel tip changed my vitreoretinal surgery
M. Ruiz Spain
Atraumatic ILM peeling: innovation in Macular Hole surgery
D. Chow Canada
My first 3 years with the integrated Digital Assisted Surgery platform
Saturday 03 October | 14:30 - 15:15
Saturday 03 October | 14:30 - 15:15

Experts in conversation: Targeting dual pathways to treat retinal diseases
Moderator(s): R. Tadayoni France P. Saharinen Finland
R. Tadayoni France P. Saharinen Finland
Experts in conversation:
- impact of anti-VEGF therapies and future perspectives
- advancing our understanding of the angiopoietin pathway
- from the bench: the role of Ang-2 in retinal disease mechanisms
- from the clinic: Ang-2 in the retina
R. Tadayoni France P. Saharinen Finland
Live discussion with the experts

Choosing your Pathway in Geographic Atrophy: Unsolved Issues and the Potential Future of Complement Inhibition
J. Monés Spain
Case studies in GA
U. Chakravarthy UK
Exploring the unmet need in GA
U. Chakravarthy UK
The role of complement in GA
J. Monés Spain
Future pathways: The potential role of C3 in GA treatment
Saturday 03 October | 14:45 - 15:30
Saturday 03 October | 14:45 - 15:30

The Digital Future: It’s here and now!
Moderator(s): N. Bressler USA
N. Bressler USA
Welcome and introduction
N. Bressler USA
Decentralized clinical trials
T. Y. Wong Singapore
Artificial intelligence and tele-ophthalmology in the post-COVID19 era
R. Hess Canada
Advances in digital therapies in ophthalmology
Saturday 03 October | 17:30 - 18:30
Saturday 03 October | 17:30 - 18:30

Let's Discuss Diabetic Eye Disease
Moderator(s): P. Mitchell Australia
P. Mitchell USA
Welcome and introduction
Panelists
The experts’ viewpoint
C. Creuzot-Garcher France
Diabetic eye disease: treat the eye or the body?
A. Tufail UK
DR screening programs: preventing vision loss?
P. Schlottmann Argentina
DME management: what have we learnt?
Panelists
How will COVID influence the future management of diabetic eye disease?
P. Mitchell USA
Conclusions

IRD: Early Identification and Accurate Diagnosis - Understanding Choroideremia and the Role of Genetic Testing
Moderator(s): A. Loewenstein Israel
J. Sahel USA
Clinical overview, epidemiology and unmet need
B. Lam USA
Clinical diagnostics: accurate, timeline diagnosis of patients with IRDs
B. LeRoy Belgium
Confirming IRDS: genetic testing
D. Fischer UK
Anatomical considerations for administration of subretinal injection
Saturday 03 October | 17:45 - 18:45
Saturday 03 October | 17:45 - 18:45

SubLiminal Laser Therapy: Where, When and How?
Moderator(s): V. Chong UK
L. Wu Costa Rica
Concept and reasons of the SubLiminal Laser approach - should we treat the fovea?
C. Kiire UK
Subliminal Laser for predominantly non-center involving DME?
A. Filloy Spain
Subliminal Laser for center involving DME: when and how?
M. Gawęcki Poland
Transfoveal SubLiminal laser treatment of CSC
V. Chong UK
Subliminal laser for AMD